Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
uniQure N.V. is a pioneering gene therapy company dedicated to developing and delivering transformative treatments for patients with severe genetic diseases. With a strong focus on AAV (Adeno-Associated Virus)-based therapies, uniQure leverages its innovative technology platform, state-of-the-art manufacturing capabilities in Lexington, MA, and Amsterdam, and deep scientific expertise to advance a pipeline of product candidates. Their lead product, HEMGENIX® (etranacogene dezaparvovec), is the first and only approved gene therapy for hemophilia B. uniQure is also advancing programs in Huntington's disease (AMT-130), amyotrophic lateral sclerosis (ALS), Fabry disease, and other rare conditions.
Serves as the company's registered office and principal executive hub, overseeing global strategy, corporate governance, finance, and European commercial operations.
Located in an area conducive to biotech innovation, likely offering modern office spaces designed to foster collaboration and support corporate functions. The proximity to other life science companies and academic institutions in the Amsterdam Science Park area is a key advantage.
Characterized by a science-driven, innovative, and patient-focused environment. Employees are typically highly skilled and dedicated to advancing gene therapy, working collaboratively towards shared goals in a dynamic and international setting.
The Amsterdam headquarters underscores uniQure's European roots and provides strategic access to European markets, regulatory agencies (like the EMA), and a diverse talent pool. It's central to their global corporate identity and operations.
uniQure maintains a significant global presence with key operational hubs in Amsterdam (Netherlands) for corporate and European activities, and Lexington (Massachusetts, USA) for extensive R&D, manufacturing, and U.S. operations. A commercial office in Zurich (Switzerland) further supports its European market engagement. This strategically distributed footprint enables uniQure to conduct global clinical trials, manage complex international manufacturing and supply chains, engage with regulatory authorities like the FDA and EMA, and execute the commercialization of its gene therapies in key markets worldwide.
Paasheuvelweg 25
Amsterdam
North Holland
Netherlands
Address: 121 Hartwell Avenue, Lexington, MA 02421, USA
Critical for uniQure's North American strategy, including R&D, manufacturing of clinical and commercial product, clinical trial execution, regulatory interactions with the FDA, and commercial activities in the U.S. market.
Address: uniQure GmbH, Zollikerstrasse 181, 8008 Zürich, Switzerland
Facilitates engagement with the Swiss healthcare ecosystem, regulatory bodies, and key opinion leaders, supporting the commercialization and patient access for uniQure's therapies in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, uniQure' leadership includes:
uniQure has been backed by several prominent investors over the years, including:
Over the past 12 months, uniQure has made significant updates to its executive team, including appointing a new Chief Operating Officer, a new Chief Financial Officer, and a new Chief People and ESG Officer. These changes were accompanied by the planned departure of the former CFO and the Chief Commercial Officer.
Discover the tools uniQure uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
uniQure commonly utilizes standard professional email formats for its employees. The most frequently observed pattern is the first initial followed by a period and the full last name, or the full first name followed by a period and the full last name, at the uniqure.com domain.
f.lastname@uniqure.com or first.lastname@uniqure.com
Format
j.doe@uniqure.com or jane.doe@uniqure.com
Example
80%
Success rate
GlobeNewswire • May 7, 2024
uniQure N.V. announced its financial results for the first quarter ended March 31, 2024, and provided updates on its pipeline, including HEMGENIX® revenues and progress in its Huntington's disease and other gene therapy programs....more
GlobeNewswire • April 4, 2024
uniQure N.V. announced the appointment of Paul Spence as its new Chief Operating Officer, effective April 15, 2024. Mr. Spence brings over two decades of experience in biopharmaceutical operations, manufacturing, and supply chain management to uniQure....more
GlobeNewswire • February 27, 2024
uniQure N.V. announced that Pierre Caloz would be appointed Chief Financial Officer, effective March 11, 2024, succeeding Christian Klemt, who departed the Company following a transition period....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including uniQure, are just a search away.